Advertisement

Topics

EHA 2019: Introduction of a new fixed-duration targeted therapy with venetoclax plus obinutuzumab in previously untreated patients with chronic lymphocytic leukaemia and coexisting comorbidities

03:30 EDT 14 Jun 2019 | ecancermedicalscience

The current standard of care for patients with chronic lymphocytic leukaemia (CLL) and coexisting conditions is fixed duration chemoimmunotherapy or continuous and indefinite targeted therapy. As an answer to an unmet clinical need we developed a new...

Original Article: EHA 2019: Introduction of a new fixed-duration targeted therapy with venetoclax plus obinutuzumab in previously untreated patients with chronic lymphocytic leukaemia and coexisting comorbidities

NEXT ARTICLE

More From BioPortfolio on "EHA 2019: Introduction of a new fixed-duration targeted therapy with venetoclax plus obinutuzumab in previously untreated patients with chronic lymphocytic leukaemia and coexisting comorbidities"

Advertisement
Quick Search
Advertisement
Advertisement